Genmab A/S announced that AbbVie Inc. has filed a complaint in the U.S. District Court for the Western District of Washington, naming Genmab, ProfoundBio US Co., ProfoundBio (Suzhou) Co., Ltd., and former AbbVie employees as defendants. AbbVie alleges misappropriation of its trade secrets related to the use of disaccharides to improve the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs), specifically concerning rinatabart sesutecan (Rina-S) and other ProfoundBio ADC pipeline products.
Genmab, which acquired ProfoundBio in May 2024, categorically refutes these allegations and stated its intention to vigorously defend against AbbVie's claims. AbbVie is seeking damages and broad injunctive reliefs, though it is not asserting any patent rights against the defendants.
Rina-S, a clinical-stage, FRα-targeted, Topo1 ADC, is currently in Phase 3 development for ovarian cancer and other FRα-expressing solid tumors. Genmab emphasized that its collaboration with AbbVie related to epcoritamab will continue unaffected during the pending lawsuit.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.